[go: up one dir, main page]

MX2018002898A - Compuestos utiles para inhibir ror-gamma-t. - Google Patents

Compuestos utiles para inhibir ror-gamma-t.

Info

Publication number
MX2018002898A
MX2018002898A MX2018002898A MX2018002898A MX2018002898A MX 2018002898 A MX2018002898 A MX 2018002898A MX 2018002898 A MX2018002898 A MX 2018002898A MX 2018002898 A MX2018002898 A MX 2018002898A MX 2018002898 A MX2018002898 A MX 2018002898A
Authority
MX
Mexico
Prior art keywords
gamma
useful compounds
ror
inhibit ror
inhibit
Prior art date
Application number
MX2018002898A
Other languages
English (en)
Other versions
MX374654B (es
Inventor
Richard Morphy John
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2018002898A publication Critical patent/MX2018002898A/es
Publication of MX374654B publication Critical patent/MX374654B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona nuevos inhibidores de ROR gamma-t y composiciones farmacéuticas de los mismos: (Ver Fórmula).
MX2018002898A 2015-09-09 2016-09-06 Compuestos útiles para inhibir ror-gamma-t. MX374654B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562215929P 2015-09-09 2015-09-09
PCT/US2016/050374 WO2017044410A1 (en) 2015-09-09 2016-09-06 Compounds useful for inhibiting ror-gamma-t

Publications (2)

Publication Number Publication Date
MX2018002898A true MX2018002898A (es) 2018-06-18
MX374654B MX374654B (es) 2025-03-06

Family

ID=56940418

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018002898A MX374654B (es) 2015-09-09 2016-09-06 Compuestos útiles para inhibir ror-gamma-t.

Country Status (41)

Country Link
US (1) US9598431B1 (es)
EP (1) EP3347360B1 (es)
JP (1) JP6282789B1 (es)
KR (1) KR102048780B1 (es)
CN (1) CN108026112B (es)
AR (1) AR105821A1 (es)
AU (1) AU2016318593B2 (es)
BR (1) BR112018001451B1 (es)
CA (1) CA2994732C (es)
CL (1) CL2018000558A1 (es)
CO (1) CO2018002440A2 (es)
CR (1) CR20180089A (es)
CY (1) CY1122287T1 (es)
DK (1) DK3347360T3 (es)
DO (1) DOP2018000066A (es)
EA (1) EA033882B1 (es)
EC (1) ECSP18018793A (es)
ES (1) ES2760992T3 (es)
HK (1) HK1249901B (es)
HR (1) HRP20192235T1 (es)
HU (1) HUE047950T2 (es)
IL (1) IL257202B (es)
JO (1) JO3638B1 (es)
LT (1) LT3347360T (es)
MA (1) MA42776B1 (es)
MD (1) MD3347360T2 (es)
MX (1) MX374654B (es)
MY (1) MY195903A (es)
NZ (1) NZ739518A (es)
PE (1) PE20181274A1 (es)
PH (1) PH12018500504A1 (es)
PL (1) PL3347360T3 (es)
PT (1) PT3347360T (es)
RS (1) RS59655B1 (es)
SI (1) SI3347360T1 (es)
SV (1) SV2018005647A (es)
TN (1) TN2018000057A1 (es)
TW (1) TWI597284B (es)
UA (1) UA118824C2 (es)
WO (1) WO2017044410A1 (es)
ZA (1) ZA201800515B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS61788B1 (sr) * 2017-03-02 2021-06-30 Lilly Co Eli Jedinjenja korisna za inhibiciju rorγt
WO2018160547A1 (en) * 2017-03-02 2018-09-07 Eli Lilly And Company Compounds useful for inhibiting ror-gamma-t
WO2018193297A1 (en) 2017-04-21 2018-10-25 Cadila Healthcare Limited Novel compounds as ror-gamma modulators
JP2020142989A (ja) * 2017-06-21 2020-09-10 Meiji Seikaファルマ株式会社 イミダゾール誘導体及びそれを含有する医薬
CN114437096B (zh) * 2020-11-06 2025-09-12 上海医药集团股份有限公司 一种螺杂环类化合物、其制备方法及应用
US20240051969A1 (en) 2020-12-07 2024-02-15 Diaccurate Ror-gamma inhibitors for the treatment of ror-gamma-dependent cancer
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016913A1 (en) * 2003-08-19 2005-02-24 Pfizer Japan, Inc. Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders
JP3790250B2 (ja) * 2004-01-16 2006-06-28 新日鐵化学株式会社 両面導体ポリイミド積層体の連続製造方法
UA107943C2 (xx) * 2009-11-16 2015-03-10 Lilly Co Eli Сполуки спіропіперидину як антагоністи рецептора orl-1
MX2012005690A (es) * 2009-11-16 2012-06-13 Lilly Co Eli Compuestos de espiropiperidina como antagonista del receptor orl-1.
KR102074089B1 (ko) * 2009-12-04 2020-02-05 선오비온 파마슈티컬스 인코포레이티드 다환형 화합물 및 이의 사용 방법
TWI582096B (zh) * 2011-12-06 2017-05-11 美國禮來大藥廠 用於酒精依賴及濫用處理之4',5'-二氫螺[哌啶-4,7'-噻吩并[2,3-c]哌喃]化合物
MX367341B (es) * 2012-05-08 2019-08-14 Merck Sharp & Dohme Tetrahidronaftiridina y compuestos biciclicos relacionados para la inhibicion de la actividad de rorgamma y el tratamiento de enfermedades.
BR112014029868A2 (pt) * 2012-05-31 2017-06-27 Phenex Pharmaceuticals Ag compostos, e, composição farmacêutica
WO2014026328A1 (en) * 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-cyclohexenyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof
WO2014179564A1 (en) 2013-05-01 2014-11-06 Vitae Pharmaceuticals, Inc. Thiazalopyrrolidine inhibitors of ror-gamma
WO2015017335A1 (en) 2013-07-30 2015-02-05 Boehringer Ingelheim International Gmbh Azaindole compounds as modulators of rorc
WO2015101928A1 (en) * 2013-12-31 2015-07-09 Aurigene Discovery Technologies Limited Fused thiophene and thiazole derivatives as ror gamma modulators

Also Published As

Publication number Publication date
HRP20192235T1 (hr) 2020-03-20
US20170066781A1 (en) 2017-03-09
DOP2018000066A (es) 2018-03-30
PE20181274A1 (es) 2018-08-03
US9598431B1 (en) 2017-03-21
TWI597284B (zh) 2017-09-01
HUE047950T2 (hu) 2020-05-28
HK1249901B (en) 2020-06-19
AU2016318593B2 (en) 2018-10-04
KR20180031777A (ko) 2018-03-28
SI3347360T1 (sl) 2019-12-31
CA2994732A1 (en) 2017-03-16
MD3347360T2 (ro) 2020-03-31
ZA201800515B (en) 2019-06-26
RS59655B1 (sr) 2020-01-31
BR112018001451B1 (pt) 2023-10-10
CO2018002440A2 (es) 2018-07-10
CL2018000558A1 (es) 2018-08-10
MY195903A (en) 2023-02-27
EP3347360A1 (en) 2018-07-18
LT3347360T (lt) 2020-01-27
EP3347360B1 (en) 2019-10-23
PL3347360T3 (pl) 2020-04-30
WO2017044410A1 (en) 2017-03-16
ECSP18018793A (es) 2018-04-30
IL257202A (en) 2018-03-29
DK3347360T3 (da) 2020-01-02
CN108026112B (zh) 2020-04-10
BR112018001451A2 (pt) 2018-09-11
CY1122287T1 (el) 2020-11-25
TN2018000057A1 (en) 2019-07-08
EA201890364A1 (ru) 2018-08-31
MA42776B1 (fr) 2020-02-28
UA118824C2 (uk) 2019-03-11
CN108026112A (zh) 2018-05-11
MX374654B (es) 2025-03-06
IL257202B (en) 2020-02-27
PT3347360T (pt) 2020-01-07
CA2994732C (en) 2020-06-30
ES2760992T3 (es) 2020-05-18
SV2018005647A (es) 2018-07-23
KR102048780B1 (ko) 2019-11-27
PH12018500504A1 (en) 2018-09-24
TW201722964A (zh) 2017-07-01
NZ739518A (en) 2019-06-28
EA033882B1 (ru) 2019-12-05
JP6282789B1 (ja) 2018-02-21
AU2016318593A1 (en) 2018-02-15
CR20180089A (es) 2018-02-27
JO3638B1 (ar) 2020-08-27
JP2018507203A (ja) 2018-03-15
AR105821A1 (es) 2017-11-15

Similar Documents

Publication Publication Date Title
ECSP18040250A (es) Composiciones y métodos para inhibir la actividad arginasa
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
PL3510033T3 (pl) Związki i kompozycje jako inhibitory endosomalnych receptorów toll- podobnych
DOP2016000125A (es) MODULADORES DE ROR GAMMA (RORy)
UY37036A (es) Compuestos inhibidores de la quinasa de unión a tank
CL2016000925A1 (es) Inhibidores de bromodominio
CO2017002532A2 (es) Indazoles sustituidos con bencilo como inhibidores de bub1
CL2017000576A1 (es) Inhibidores de mk2 y sus usos
CL2016001790A1 (es) Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2.
MX2018001430A (es) Nuevos compuestos biciclicos como inhibidores duales de autotaxina (atx)/anhidrasa carbonica (ca).
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
CO2017011151A2 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
MX2015009719A (es) Inhibidores benzoquinolona de vmat2.
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t
CR20180143A (es) Nuevos compuestos biciclicos como inhibidores duales de atx/ca
DOP2018000062A (es) Piridinona dicaboxamidas para uso como inhibidores de bromodominio
MX373320B (es) Compuestos inhibidores de pde2.
CL2016000568A1 (es) Compuestos derivados de 2h-indazol-2-il-n-hidroxi-2-metilsulfonil-2-metil-butanamida sustituidos o sus sales; sus composiciones farmacéuticas que los contiene y su uso para la prevención y/o tratamiento de infecciones bacterianas gram-negativas.
MX2016000219A (es) Compuestos neurotransmisores de dihidroxifenilo, composiciones y metodos.
MX2018000175A (es) Compuestos de arilsulfonamida como inhibidores de la anhidrasa carbonica y su uso terapeutico.
MX2017014880A (es) Composiciones farmaceuticas y uso de las mismas.
UY36464A (es) Compuestos de quinazolina

Legal Events

Date Code Title Description
FG Grant or registration